TY - JOUR
T1 - Meta-analysis of Clinical Outcomes Using Ceftazidime/Avibactam, Ceftolozane/Tazobactam, and Meropenem/Vaborbactam for the Treatment of Multidrug-Resistant Gram-Negative Infections
AU - Wilson, Geneva M.
AU - Fitzpatrick, Margaret
AU - Walding, Kyle
AU - Gonzalez, Beverly
AU - Schweizer, Marin L.
AU - Suda, Katie J.
AU - Evans, Charlesnika T.
N1 - Funding Information:
This work was supported by The Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, IIR 16-028 (PI: Evans, Charlesnika).
Publisher Copyright:
© 2021 Published by Oxford University Press on behalf of Infectious Diseases Society of America 2021.
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Ceftolozane-tazobactam (C/T), ceftazidime-avibactam (C/A), and meropenem/vaborbactam (M/V) are new beta-lactam/beta-lactamase combination antibiotics commonly used to treat multidrug-resistant Pseudomonas aeruginosa (MDRPA) and carbapenem-resistant Enterobacteriaceae (CRE) infections. This review reports the clinical success rates for C/T, C/A, and M/V. PubMed and EMBASE were searched from January 1, 2012, through September 2, 2020, for publications detailing the use of C/T, C/A, and M/V. A meta-analysis determined the pooled effectiveness of C/T, C/A, and M/V. The literature search returned 1950 publications; 29 publications representing 1620 patients were retained. Pneumonia was the predominant infection type (49.8%). MDRPA was the major pathogen treated (65.3%). The pooled clinical success rate was 73.3% (95% CI, 68.9%-77.5%). C/T, C/A, or M/V resistance was reported in 8.9% of the population. These antibiotics had a high clinical success rate in patients with complicated infections and limited treatment options. Larger studies comparing C/T, C/A, and M/V against other antibiotic regimens are needed.
AB - Ceftolozane-tazobactam (C/T), ceftazidime-avibactam (C/A), and meropenem/vaborbactam (M/V) are new beta-lactam/beta-lactamase combination antibiotics commonly used to treat multidrug-resistant Pseudomonas aeruginosa (MDRPA) and carbapenem-resistant Enterobacteriaceae (CRE) infections. This review reports the clinical success rates for C/T, C/A, and M/V. PubMed and EMBASE were searched from January 1, 2012, through September 2, 2020, for publications detailing the use of C/T, C/A, and M/V. A meta-analysis determined the pooled effectiveness of C/T, C/A, and M/V. The literature search returned 1950 publications; 29 publications representing 1620 patients were retained. Pneumonia was the predominant infection type (49.8%). MDRPA was the major pathogen treated (65.3%). The pooled clinical success rate was 73.3% (95% CI, 68.9%-77.5%). C/T, C/A, or M/V resistance was reported in 8.9% of the population. These antibiotics had a high clinical success rate in patients with complicated infections and limited treatment options. Larger studies comparing C/T, C/A, and M/V against other antibiotic regimens are needed.
KW - antimicrobial resistance
KW - epidemiology
KW - meta-analysis
KW - multidrug-resistant infections
UR - http://www.scopus.com/inward/record.url?scp=85103318623&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103318623&partnerID=8YFLogxK
U2 - 10.1093/ofid/ofaa651
DO - 10.1093/ofid/ofaa651
M3 - Article
C2 - 33598503
AN - SCOPUS:85103318623
SN - 2328-8957
VL - 8
JO - Open Forum Infectious Diseases
JF - Open Forum Infectious Diseases
IS - 2
M1 - ofaa651
ER -